Guest guest Posted July 23, 2003 Report Share Posted July 23, 2003 Subject: CF: Growth and nutritional indexes in early life predict pulmonary function in cystic fibrosis (CF). J Pediatr 2003;142:624-30 June 2003 . Volume 142 . Number 6 Original Articles Growth and nutritional indexes in early life predict pulmonary function in cystic fibrosis W. Konstan, MD [MEDLINE LOOKUP] M. , PhD [MEDLINE LOOKUP] Ellen B. Wohl, MD [MEDLINE LOOKUP] Marcia Stoddard, BS [MEDLINE LOOKUP] Matousek, MS [MEDLINE LOOKUP] S. Wagener, MD [MEDLINE LOOKUP] A. , MBChB [MEDLINE LOOKUP] Wayne J. , MD [MEDLINE LOOKUP] Abstract Objective To determine the relation of growth and nutritional status to pulmonary function in young children with cystic fibrosis (CF). Study design The relation of weight-for-age (WFA), height-for-age (HFA), percent ideal body weight (%IBW), and signs of lung disease at age 3 years with pulmonary function at age 6 years was assessed in 931 patients with CF. Associations of changes in WFA from age 3 to 6 on pulmonary function were also assessed. Results WFA, HFA, and %IBW were poorly associated with lung disease at age 3 years, but all were strongly associated with pulmonary function at age 6 years. Those with WFA below the 5th percentile at age 3 had lower pulmonary function at age 6 compared with those above the 75th percentile (FEV1: 86 ± 20 [sD] versus 102 ± 18 % predicted, respectively). Pulmonary function was highest in those whose WFA remained >10th percentile from age 3 to 6 (FEV1: 100 ± 19 % predicted) and lowest in those who remained <10th percentile (84 ± 21 % predicted). Patients with signs and symptoms of lung disease at age 3 years had lower pulmonary function at age 6 years. Conclusions Aggressive intervention early in life aimed at growth and nutrition and/or lung disease may affect pulmonary function. (J Pediatr 2003;142:624-30) Publishing and Reprint Information From the Department of Pediatrics, Rainbow Babies and Children's Hospital and Case Western Reserve University School of Medicine, Cleveland, Ohio; Medical Affairs, Genentech, South San Francisco, California; the Department of Pediatrics, Children's Hospital and Harvard Medical School, Boston, Massachusetts; the Department of Pediatrics, The Children's Hospital and University of Colorado School of Medicine, Denver, Colorado; and the Departments of Pediatrics and Physiology, University of Arizona, Tucson, Arizona. Genentech, Inc, funds the Epidemiologic Study of Cystic Fibrosis. Drs Konstan, Wohl, Wagener, and are members of the scientific advisory board for the Epidemiologic Study of Cystic Fibrosis and have received grants and other support from Genentech, Inc. Submitted for publication Jan 28, 2002; revisions received Aug 13, 2002, and Dec 23, 2002; accepted Jan 16, 2003. Reprint requests: W. Konstan, MD, Rainbow Babies and Children's Hospital, 11100 Euclid Ave, Cleveland, OH 44106. E-mail: mwk3@... . for the Investigators Coordinators of the Epidemiologic Study of Cystic Fibrosis Copyright © 2003, Mosby, Inc. All rights reserved. Peace Torsten, dad of Fiona 6wcf and Sebastian newborn wocf e-mail: torstenkrafft@... Quote Link to comment Share on other sites More sharing options...
Recommended Posts
Join the conversation
You are posting as a guest. If you have an account, sign in now to post with your account.
Note: Your post will require moderator approval before it will be visible.